ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis Sells 1,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Krista Davis also recently made the following trade(s):

• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00.

ANI Pharmaceuticals Trading Down 4.1 %

ANI Pharmaceuticals stock opened at $55.57 on Tuesday. The firm has a 50 day simple moving average of $57.06 and a 200-day simple moving average of $58.20. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a market capitalization of $1.17 billion, a PE ratio of -101.04 and a beta of 0.74. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock valued at $2,648,000 after acquiring an additional 13,948 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter valued at approximately $1,128,000. Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter valued at approximately $200,000. ProShare Advisors LLC lifted its stake in ANI Pharmaceuticals by 29.0% during the fourth quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock valued at $361,000 after purchasing an additional 1,469 shares during the last quarter. Finally, Nomura Holdings Inc. lifted its stake in ANI Pharmaceuticals by 1.5% during the fourth quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock valued at $11,823,000 after purchasing an additional 3,255 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ANIP shares. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.